Results 51 to 60 of about 27,286 (132)

Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response. [PDF]

Br J Cancer, 2018
Poor drug response of sorafenib is a major challenge which reduces clinical benefit of renal cell carcinoma (RCC) patients. It is therefore of great clinical significance to elucidate the underlying mechanism to restore the therapeutic response to sorafenib.Angiopoietin-like protein 3 (ANGPTL3) protein levels were measured by western blot and ...
Bao Y, Yang F, Liu B, Zhao T, Xu Z, Xiong Y, Sun S, Qu L, Wang L.   +8 more
europepmc   +4 more sources

Clinical significance of angiopoietin-like protein 3 expression in patients with glioblastoma

Neoplasma, 2016
There is strong evidence that angiopoietin-like peptide family is involved in the invasiveness and metastasis of cancer. Angiopoietin-like protein 3 (ANGPTL3) is proven to be involved in angiogenesis and tumor development. However, there is no published data on the role ANGPLT3 plays in glioblastomas.
P F, Wang, H L, Li, X, Qi, K, Yao, S, Han, N, Liu, Y K, Yang, S W, Li, C X, Yan   +8 more
openaire   +3 more sources

ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting

Frontiers in Endocrinology
Despite achieving recommended low-density lipoprotein cholesterol (LDL-C) targets, many patients remain at high risk of cardiovascular events due to elevated triglyceride-rich lipoproteins and remnants.
Shuwei Weng, Shuwei Weng, Chen Ding, Chen Ding, Jinxiu Lin, Jinxiu Lin, Dajun Chai, Dajun Chai   +7 more
doaj   +1 more source

Phosphoglycerate Mutase 5 Is Important Mediator for Instigating Arterial Lipid Accumulation and Aggravating Atherosclerosis

JACC: Basic to Translational Science
Summary: Although the receptor-interacting protein kinase-3 (RIPK3)–phosphoglycerate mutase 5 (PGAM5) signaling pathway is activated in other disease models, its role in atherosclerotic lesions remains unclear.
Qian Zhang, PhD, Peng Zheng, MD, Yang Pan, MD, Hanxiao Zhou, MD, Yahong Fu, PhD, Enzhi Jia, MD, PhD   +5 more
doaj   +1 more source

Olezarsen and Beyond: Emerging Targeted Treatments for Familial Chylomicronemia Syndrome and Related Triglyceride Disorders

Journal of Lipid and Atherosclerosis
In familial chylomicronemia syndrome (FCS), a rare lipid disorder, triglycerides rise to extremely high levels because of the inability to utilize lipoprotein lipase (LPL) for fat metabolism. Traditional triglyceride-lowering medications are ineffective,
Meghashree N, Kushal C B, Shivaraj D R
doaj   +1 more source

Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report

Pharmaceuticals, 2023
Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by the U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years ...
Alice Fachin, Chiara De Carlo, Alessandra Maestro, Davide Zanon, Egidio Barbi, Natalia Maximova   +5 more
doaj   +1 more source

Human adaptation to high altitude: a review of convergence between genomic and proteomic signatures

Human Genomics, 2022
Both genomics- and proteomics-based investigations have identified several essential genes, proteins, and pathways that may facilitate human adaptive genotype/phenotype in a population-specific manner.
Vandana Sharma, Rajeev Varshney, Niroj Kumar Sethy   +2 more
doaj   +1 more source

The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy

Journal of Translational Medicine
Background Breakdown of the blood-retinal barrier (BRB) is a key driver of diabetic retinopathy (DR). While Angiopoietin-like protein 3 (ANGPTL3) is a clinical predictor of DR, its causal role and mechanism in retinal vascular pathology are unknown ...
Jing Ke, Yongsong Xu, Yingjun Zhu, Xiaotong Feng, Haodi Cao, Longyan Yang, Dong Zhao   +6 more
doaj   +1 more source

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Journal of Lipid and Atherosclerosis
Apolipoprotein C3 (apoC3) and angiopoietin-like protein 3 (ANGPTL3) inhibit lipolysis by lipoprotein lipase and may influence the secretion and uptake of various lipoproteins.
Brian Tomlinson, Qian-yan Wu, Yi-ming Zhong, Yan-hong Li   +3 more
doaj   +1 more source

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion1[S]

Journal of Lipid Research, 2015
Humans and mice lacking angiopoietin-like protein 3 (ANGPTL3) have pan-hypolipidemia. ANGPTL3 inhibits two intravascular lipases, LPL and endothelial lipase, and the low plasma TG and HDL-cholesterol levels in ANGPTL3 deficiency reflect increased ...
Yan Wang, Viktoria Gusarova, Serena Banfi, Jesper Gromada, Jonathan C. Cohen, Helen H. Hobbs   +5 more
doaj   +1 more source